Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Clinical trial NCT04276493 · COMPLETED

Trial details

NCT number: NCT04276493
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Breast Cancer Gastric Cancer Gastroesophageal Junction Cancer

Start date: 2020-03-26
Primary completion: 2023-12-07
Enrollment: 71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.